The Chemours Company (NYSE:CC) Shares Bought by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. boosted its position in shares of The Chemours Company (NYSE:CCGet Rating) by 11.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 15,841 shares of the specialty chemicals company’s stock after acquiring an additional 1,636 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Chemours were worth $499,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hancock Whitney Corp lifted its position in Chemours by 1.5% during the 1st quarter. Hancock Whitney Corp now owns 18,442 shares of the specialty chemicals company’s stock worth $581,000 after acquiring an additional 265 shares during the period. AdvisorNet Financial Inc lifted its position in Chemours by 63.2% during the 1st quarter. AdvisorNet Financial Inc now owns 785 shares of the specialty chemicals company’s stock worth $25,000 after acquiring an additional 304 shares during the period. Comerica Bank lifted its position in Chemours by 0.4% during the 1st quarter. Comerica Bank now owns 77,443 shares of the specialty chemicals company’s stock worth $2,761,000 after acquiring an additional 326 shares during the period. AE Wealth Management LLC lifted its position in Chemours by 5.8% during the 1st quarter. AE Wealth Management LLC now owns 6,614 shares of the specialty chemicals company’s stock worth $208,000 after acquiring an additional 361 shares during the period. Finally, Baird Financial Group Inc. lifted its position in Chemours by 4.3% during the 1st quarter. Baird Financial Group Inc. now owns 10,390 shares of the specialty chemicals company’s stock worth $327,000 after acquiring an additional 426 shares during the period. Institutional investors and hedge funds own 70.86% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CC. Bank of America lowered Chemours from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $48.00 to $44.00 in a research note on Tuesday, June 14th. Royal Bank of Canada lifted their price objective on Chemours from $44.00 to $48.00 and gave the company an “outperform” rating in a research note on Monday, August 1st. StockNews.com upgraded Chemours from a “buy” rating to a “strong-buy” rating in a research note on Thursday. UBS Group lifted their price target on Chemours from $35.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, July 29th. Finally, Citigroup lifted their price target on Chemours to $36.00 in a research note on Tuesday, August 9th. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.17.

Chemours Trading Down 6.9 %

Shares of Chemours stock opened at $31.49 on Monday. The stock has a market cap of $4.89 billion, a P/E ratio of 5.88, a P/E/G ratio of 0.39 and a beta of 1.80. The stock’s 50 day simple moving average is $34.51 and its 200-day simple moving average is $34.56. The Chemours Company has a 1-year low of $22.56 and a 1-year high of $44.95. The company has a debt-to-equity ratio of 3.01, a current ratio of 1.91 and a quick ratio of 1.27.

Chemours (NYSE:CCGet Rating) last issued its earnings results on Thursday, July 28th. The specialty chemicals company reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.47. Chemours had a return on equity of 79.77% and a net margin of 12.72%. The business had revenue of $1.92 billion for the quarter, compared to analysts’ expectations of $1.84 billion. During the same period in the previous year, the firm posted $1.20 EPS. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. Analysts predict that The Chemours Company will post 5.6 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 15th. Investors of record on Monday, August 15th were issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend was Friday, August 12th. Chemours’s dividend payout ratio is presently 18.66%.

Chemours Profile

(Get Rating)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

See Also

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CCGet Rating).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.